-
公开(公告)号：US20190127119A1
公开(公告)日：2019-05-02
申请号：US16094013
申请日：2016-04-25
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Shigehiko Kokubo
Abstract: A container includes a container body; and a cap that locks onto the container body, the container body and the cap being locked by putting the cap on the container body. The cap includes a cap body, a cover cap being held on the cap body so as to be displaceable and rotatable, and an urging portion that upwardly urges the cover cap. When a rotational force is applied to the cover cap being downwardly pressed, the cap body is displaced in conjunction with the cover cap, so that locking between the cap body and the container body is released, and in a state where the cover cap is not downwardly pressed, the cap body is not displaced in conjunction with the cover cap even when a rotational force is applied to the cover cap, so that locking between the cap body and the container body is not released.
-
公开(公告)号：USD840821S1
公开(公告)日：2019-02-19
申请号：US29581595
申请日：2016-10-20
Applicant: Rohto Pharmaceutical Co., Ltd.
Designer： Shigehiko Kokubo
-
公开(公告)号：US20190015452A1
公开(公告)日：2019-01-17
申请号：US15749766
申请日：2016-08-03
Applicant: OSAKA UNIVERSITY , ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Kohji NISHIDA , Ryuuhei HAYASHI , Yoichi HONMA , Toru OKUBO , Shun SHIBATA
IPC: A61K35/28 , A61P27/02 , C12N5/0775 , C12N5/00
Abstract: The present invention relates to mesenchymal stem cell-derived microparticles having activity that promotes the growth of corneal epithelial stem cells and/or corneal epithelial cells, activity that maintains corneal epithelial stem cells in an undifferentiated state or promotes the formation of colonies thereby, and function that protects corneal epithelium.
-
14.发明申请公开(公告)号：US20180364216A1
公开(公告)日：2018-12-20
申请号：US16063047
申请日：2016-12-16
Applicant: Link Genomics, Inc. , ROHTO Pharmaceutical Co., Ltd.
Inventor： Shinichiro Niwa , Dai Ogura , Hidemi Mizunuma , Yoko Arai , Takahiro Kurose , Yoshihiro Takai , Yoko Mitsuguchi , Mariyo Moriya
IPC: G01N33/50 , A61K31/192 , A61K31/404 , A61K31/38 , A61K31/421 , A61K31/426 , A61K31/436 , A61P27/02
Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.
-
公开(公告)号：US09173945B2
公开(公告)日：2015-11-03
申请号：US14355350
申请日：2012-10-31
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Yasuko Matsumura , Chinatsu Furumiya , Masashi Itoh
IPC: A61F2/00 , A61K47/38 , A61K9/08 , A61K31/045 , A61K31/122 , A61K31/125 , A61K33/30 , A61K9/00 , A61K47/10 , A61K47/32 , A61K47/36
CPC classification number: A61K47/38 , A61K9/0048 , A61K9/08 , A61K31/045 , A61K31/122 , A61K31/125 , A61K33/30 , A61K47/10 , A61K47/32 , A61K47/36 , A61K2300/00
Abstract: The present invention provides an aqueous ophthalmic composition containing (A) a terpenoid, (B) zinc chloride, and (C) at least one member selected from the group consisting of cellulose-based polymeric compounds, vinyl-based polymeric compounds, polyethylene glycols and dextran. According to the present invention, an aqueous ophthalmic composition is provided in which adsorption of the terpenoid to a container can be inhibited, thereby making it possible to inhibit the reduction in the terpenoid content for a long period of time, the aqueous ophthalmic composition having some excellent actions such as an inhibitory action for histamine release, and an inhibitory action for discharges from the eyes.
Abstract translation: 本发明提供含有（A）萜类化合物，（B）氯化锌和（C）至少一种选自纤维素基聚合物，乙烯基类聚合物，聚乙二醇和 葡聚糖 根据本发明，提供一种眼科组合物，其中可以抑制萜类化合物对容器的吸附，从而可以长时间抑制萜类化合物含量的降低，眼用组合物具有一些 优良的作用如对组胺释放的抑制作用，以及从眼睛排出的抑制作用。
-
Patent Agency Ranking
公开(公告)号：US20150064281A1
公开(公告)日：2015-03-05
申请号：US14391559
申请日：2013-04-04
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Kazuhiro Fukushima , Mariyo Kato , Yoshihiro Takai , Masashi Itoh
IPC: A61K31/155 , A61K33/30
CPC classification number: A61K31/155 , A61K31/785 , A61K33/22 , A61K33/30 , A61L12/142 , A61K2300/00
Abstract: The present invention provides an ophthalmic composition containing (A) a biguanide-based disinfectant and (B) zinc chloride. According to the present invention, an ophthalmic composition having remarkably increased disinfection effects against Acanthamoeba is provided.
Abstract translation: 本发明提供含有（A）双胍类消毒剂和（B）氯化锌的眼用组合物。 根据本发明，提供了对棘阿米巴具有显着提高的消毒效果的眼用组合物。
-
公开(公告)号：US20140308368A1
公开(公告)日：2014-10-16
申请号：US14355350
申请日：2012-10-31
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Yasuko Matsumura , Chinatsu Furumiya , Masashi Itoh
IPC: A61K47/38 , A61K31/122 , A61K47/36 , A61K33/30 , A61K47/32 , A61K47/10 , A61K31/045 , A61K31/125
CPC classification number: A61K47/38 , A61K9/0048 , A61K9/08 , A61K31/045 , A61K31/122 , A61K31/125 , A61K33/30 , A61K47/10 , A61K47/32 , A61K47/36 , A61K2300/00
Abstract: The present invention provides an aqueous ophthalmic composition containing (A) a terpenoid, (B) zinc chloride, and (C) at least one member selected from the group consisting of cellulose-based polymeric compounds, vinyl-based polymeric compounds, polyethylene glycols and dextran. According to the present invention, an aqueous ophthalmic composition is provided in which adsorption of the terpenoid to a container can be inhibited, thereby making it possible to inhibit the reduction in the terpenoid content for a long period of time, the aqueous ophthalmic composition having some excellent actions such as an inhibitory action for histamine release, and an inhibitory action for discharges from the eyes.
Abstract translation: 本发明提供含有（A）萜类化合物，（B）氯化锌和（C）至少一种选自纤维素基聚合物，乙烯基类聚合物，聚乙二醇和 葡聚糖 根据本发明，提供一种眼科组合物，其中可以抑制萜类化合物对容器的吸附，从而可以长时间抑制萜类化合物含量的降低，眼用组合物具有一些 优良的作用如对组胺释放的抑制作用，以及从眼睛排出的抑制作用。
-
公开(公告)号：US20140128475A1
公开(公告)日：2014-05-08
申请号：US14154688
申请日：2014-01-14
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Takahiro KUROSE , Takayuki MIYANO , Mariyo KATO , Yoshihiro TAKAI
IPC: A61K31/121 , A61K45/06
CPC classification number: A61K31/121 , A61K9/0048 , A61K9/0053 , A61K45/06 , A61K47/02 , A61K47/26 , A61K47/44
Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which(a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.
Abstract translation: （5E，9E，13E）ger anyl ger anyl anyl anyl one one and，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，， 13E）ger anyl ger anyl anyl anyl one one death death death death death death，，，，，death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death 的视网膜细胞，从而从根本上防止，改善或治疗视网膜疾病。
-
公开(公告)号：US20130303627A1
公开(公告)日：2013-11-14
申请号：US13775644
申请日：2013-02-25
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Takayuki MIYANO , Takahiro KUROSE
CPC classification number: A61K47/10 , A61K9/0048 , A61K9/06 , A61K9/08 , A61K31/121 , A61K47/14 , A61K47/22 , A61K47/44
Abstract: An ophthalmic composition comprising geranylgeranylacetone and a fat-soluble antioxidant has an advantage that adsorption of geranylgeranylacetone to a wall of a container is remarkably reduced and thereby the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the composition is remarkably reduced. Adsorption of the fat-soluble antioxidant to a wall of a container is also reduced due to combination with geranylgeranylacetone.
-
公开(公告)号：US20230285564A1
公开(公告)日：2023-09-14
申请号：US18018108
申请日：2021-07-30
Applicant: Rohto Pharmaceutical Co., Ltd.
Inventor： Ozora Kubo , Saeko Hayashi , Akiko Kita
IPC: A61K47/22 , A61K9/00 , A61K9/08 , A61K47/18 , A61K31/519
CPC classification number: A61K47/22 , A61K9/0048 , A61K9/08 , A61K47/183 , A61K31/519
Abstract: The present invention relates to an aqueous composition comprising delgocitinib or a salt thereof (A) and at least one selected from the group consisting of edetic acid, creatinine, and a salt thereof (B).
-
-
-
-
-
-
-
-
-
Search Results
118
records
(took 0.027 seconds)
